BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Audenaerde JRM, Roeyen G, Darcy PK, Kershaw MH, Peeters M, Smits ELJ. Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. Pharmacol Ther. 2018;189:31-44. [PMID: 29660367 DOI: 10.1016/j.pharmthera.2018.04.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun H, Shi K, Qi K, Kong H, Zhang J, Dai S, Ye W, Deng T, He Q, Zhou M. Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. Front Immunol 2019;10:2819. [PMID: 31921112 DOI: 10.3389/fimmu.2019.02819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
2 Yang SZ, Xu F, Yuan K, Sun Y, Zhou T, Zhao X, McDonald JM, Chen Y. Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation. Lab Invest 2020;100:777-85. [PMID: 31896813 DOI: 10.1038/s41374-019-0365-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liu Y, Feng M, Chen H, Yang G, Qiu J, Zhao F, Cao Z, Luo W, Xiao J, You L, Zheng L, Zhang T. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Cancer Lett 2020;485:1-13. [PMID: 32428662 DOI: 10.1016/j.canlet.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Jun E, Song AY, Choi JW, Lee HH, Kim MY, Ko DH, Kang HJ, Kim SW, Bryceson Y, Kim SC, Kim HS. Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-β1 Deregulation and Disease Progression in Pancreatic Cancer. Front Immunol 2019;10:1354. [PMID: 31281312 DOI: 10.3389/fimmu.2019.01354] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
5 [DOI: 10.1101/330209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Thakur G, Kumar R, Kim SB, Lee SY, Lee SL, Rho GJ. Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma. Biomedicines 2021;9:178. [PMID: 33670230 DOI: 10.3390/biomedicines9020178] [Reference Citation Analysis]
7 Papademetrio DL, Garcia MN, Grasso D, Alvarez É. Autophagy-Mediated Exosomes as Immunomodulators of Natural Killer Cells in Pancreatic Cancer Microenvironment. Front Oncol 2020;10:622956. [PMID: 33680945 DOI: 10.3389/fonc.2020.622956] [Reference Citation Analysis]
8 Kim JM, Yi E, Cho H, Choi WS, Ko DH, Yoon DH, Hwang SH, Kim HS. Assessment of NK Cell Activity Based on NK Cell-Specific Receptor Synergy in Peripheral Blood Mononuclear Cells and Whole Blood. Int J Mol Sci 2020;21:E8112. [PMID: 33143099 DOI: 10.3390/ijms21218112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Hung YH, Chen LT, Hung WC. The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy. Biomedicines 2022;10:926. [PMID: 35453676 DOI: 10.3390/biomedicines10040926] [Reference Citation Analysis]
10 Francescone R, Barbosa Vendramini-Costa D, Franco-Barraza J, Wagner J, Muir A, Lau AN, Gabitova L, Pazina T, Gupta S, Luong T, Rollins D, Malik R, Thapa RJ, Restifo D, Zhou Y, Cai KQ, Hensley HH, Tan Y, Kruger WD, Devarajan K, Balachandran S, Klein-Szanto AJ, Wang H, El-Deiry WS, Vander Heiden MG, Peri S, Campbell KS, Astsaturov I, Cukierman E. Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast-Driven Nutritional Support and Immunosuppression. Cancer Discov 2021;11:446-79. [PMID: 33127842 DOI: 10.1158/2159-8290.CD-20-0775] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
11 Yang J, Lin P, Yang M, Liu W, Fu X, Liu D, Tao L, Huo Y, Zhang J, Hua R, Zhang Z, Li Y, Wang L, Xue J, Li H, Sun Y. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma. Genome Biol 2021;22:4. [PMID: 33397441 DOI: 10.1186/s13059-020-02222-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Liao X, Huang R, Wang X, Huang K, Yang C, Zhou X, Han C, Su H, Ye X, Liu K, Zhu G, Peng T. UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy. J Cancer 2021;12:2122-39. [PMID: 33754011 DOI: 10.7150/jca.46084] [Reference Citation Analysis]
13 Mu W, Wang Z, Zöller M. Ping-Pong-Tumor and Host in Pancreatic Cancer Progression. Front Oncol 2019;9:1359. [PMID: 31921628 DOI: 10.3389/fonc.2019.01359] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
14 Geismann C, Erhart W, Grohmann F, Schreiber S, Schneider G, Schäfer H, Arlt A. TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines. Int J Mol Sci 2018;19:E1661. [PMID: 29867042 DOI: 10.3390/ijms19061661] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
15 Fincham REA, Delvecchio FR, Goulart MR, Yeong JPS, Kocher HM. Natural killer cells in pancreatic cancer stroma. World J Gastroenterol 2021; 27(24): 3483-3501 [PMID: 34239264 DOI: 10.3748/wjg.v27.i24.3483] [Reference Citation Analysis]
16 Zhang H, Zhu Y, Wang J, Weng S, Zuo F, Li C, Zhu T. PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells. Cell Signal 2021;86:110115. [PMID: 34375670 DOI: 10.1016/j.cellsig.2021.110115] [Reference Citation Analysis]
17 Li Y, Harunori O, Fu S, Xing F, Wu H, Wang J, Chen A, Ren X, Peng D, Ling X, Shi M, Wu H. Immune normalization strategy against suboptimal health status: safe and efficacious therapy using mixed-natural killer cells. Aging (Albany NY) 2021;13:20131-48. [PMID: 34461606 DOI: 10.18632/aging.203279] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Han S, Underwood P, Hughes SJ. From tumor microenvironment communicants to biomarker discovery: Selectively packaged extracellular vesicular cargoes in pancreatic cancer. Cytokine Growth Factor Rev 2020;51:61-8. [PMID: 32005635 DOI: 10.1016/j.cytogfr.2020.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]